解鎖個性化癌症護理。 立即預約檢測
解鎖個性化癌症護理。 立即預約檢測
陣列比較基因組雜交（aCGH）測試，一種基於微陣列的技術，是當今最精確的工具，能檢測出癌症患者中存在的不平衡結構和數量染色體異常。當患者被診斷可能患上未知來源的癌症時，該測試會相當有幫助。在這種情況下，aCGH通過識別與特定類型癌症相關的染色體異常，幫助醫生指引正確方向。
aCGH是一種強大的技術，能夠比較來自兩組基因的DNA含量：一個測試（或患者）基因組和一個參考（或對照）基因組。染色體經歷許多異常，如基因中一個或多個片段的增加、缺失或結構變化。aCGH能夠檢測到這些基因中的染色體異常。
這項綜合分析有助於理解導致疾病的潛在遺傳因素。通過識別染色體異常，有助於確定原發腫瘤的潛在位置，為診斷和治療計劃提供關鍵信息。
With the detection of abnormalities in the chromosomes, aCGH enables us to identify the type of cancer the patient has been affected with.
It enables precise and fast detection of abnormalities in the entire genome sequence with very high resolution.
It provides clinicians with personalized chromosomal analysis for their unique cancer journey.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Whole peripheral blood sample
10-15 ml of whole peripheral blood
2-3 weeks in the lab
30 days after sample collection
Applicable for all cancer types
To whom it is relevant: The test is recommended for patients with a confirmed cancer diagnosis.
©2024 版權所有 不得轉載. Designed by Bee High Media.
